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demonstrated that intravenous infusion of MSC leads to accumula-
tion of the cells in the lungs and that they disappear within 24 h, 
after which they cannot be detected in other tissues. This suggests 
that MSC are short-lived after infusion and that their effects are 
transferred to other cell types.
Chen et al. (2012) reviewed the clinical potential of MSC-based 
regenerative therapy for chronic wounds. Studies have shown 
that MSC administration augments the acute inflammatory 
response, enhances angiogenesis, accelerates re-epithelialization, 
and increases wound healing, even in conditions of impaired heal-
ing such as diabetes. However, whether MSC induced cutaneous 
regeneration by cellular differentiation or indirectly through par-
acrine activity is still unknown. A better understanding of the 
mechanism of action is needed to develop more efficient treat-
ment strategies. Also, further investigation into delivery methods 
specifically designed for the delivery of progenitor cells to chronic 
wounds is necessary to maximize the regenerative properties of 
MSC-based cell therapy.
Different studies have reported beneficial effects of human MSC 
on repair of ischemia-reperfusion and other acute kidney injury, 
as discussed by de Vries et al. (2012). The therapeutic potential of 
human MSC was studied in immunodeficient NOD-SCID mice 
after cisplatin-induced acute renal failure; MSC reduced renal cell 
apoptosis and increased proliferation. MSC also preserved the 
integrity of the tubular epithelium and peritubular vessels, and 
prolonged survival.
Mechanistically, there is growing evidence that the process of 
transdifferentiation is unlikely to be relevant to renal repair in vivo. 
The primary means of these cells most likely involve paracrine 
and endocrine effects, including mitogenic, anti-apoptotic, anti-
inflammatory, antifibrotic, and angiogenic influences. The factors 
that mediate the paracrine effects are obviously of great interest. 
Several factors that are abundant in MSC-conditioned medium 
have been mentioned, including microvesicles released from MSC 
may account for this paracrine mechanism.
Seifert et al. (2012) warn that treatment with both donor- 
and recipient-specific MSC in a preclinical kidney transplanta-
tion model surprisingly resulted in enhanced humoral immune 
responses. Signs of inflammation and rejection were generally 
enhanced in both MSC-treated groups compared to PBS control 
groups. Additionally, pre-treatment with donor-specific MSC sig-
nificantly enhanced the level of donor-specific antibody forma-
tion when compared with PBS- or recipient MSC-treated groups. 
Pre-treatment with both MSC types resulted in a higher degree of 
kidney cortex tissue damage and elevated creatinine levels at the 
Mesenchymal stem cells (MSC) are emerging as a therapeutic 
option for a plethora of immunological and degenerative dis-
eases. Preclinical research is focusing on the mechanisms of MSC-
mediated immunomodulation and regeneration. This Research 
Topic shines light on mechanistic and regulatory aspects that are 
of importance for understanding the full potential of MSC for 
clinical use in transplantation and tissue regeneration.
A first consideration to make when studying MSC that is 
addressed in this Research Topic is the source of the cells. MSC 
are present in bone marrow and adipose tissue, amongst other 
tissues, and can be used in an autologous or allogeneic way. A 
commercially available allogeneic “off the shelf ” cell product as 
described by Vaes et al. (2012) has the advantage that it is thor-
oughly characterized and can be produced at a relatively low cost, 
although for particular applications in transplantation autologous 
cell usage may be preferable because of the expression of HLA 
class I on MSC and the potential risk of sensitization upon the 
use of allogeneic MSC.
Functionally, MSC are influenced by environmental factors. Leijs 
et al. (2012) demonstrated that synovial fluid of arthritic patients 
modulates the expression of genes with immunomodulatory func-
tion in MSC. Also, toll-like receptor activation by pathogen-derived 
components or danger signals produced upon tissue injury can 
modulate MSC toward either an anti-inflammatory or a pro-
inflammatory phenotype and alter their function (Delarosa et al., 
2012). The local milieu appears therefore crucial in the therapeutic 
effect of MSC.
It becomes more and more clear that multiple mechanisms are 
responsible for the immunomodulatory effect of MSC. Different 
mechanisms target a variety of facets of immune cell functioning. 
For instance, as shown by Zinocker and Vaage (2012). The inhibi-
tion of T cell proliferation by rat MSC is dependent on nitric oxide, 
whereas cytokine production is modulated by the production of 
prostaglandin E2 by MSC. Interest is rising in the effect of MSC on 
B cells, as B cells are increasingly held responsible for transplant 
rejection. MSC can inhibit immunoglobulin production by B cells 
and may induce regulatory B cells, although the conditions under 
which this takes place are not clear yet, as lined out by Franquesa 
et al. (2012). More is known about the effect of MSC on regulatory 
T cells. Engela et al. (2012) reviewed studies that demonstrate the 
induction of regulatory T cells by MSC in vitro and in vivo after 
infusion. Although MSC and regulatory T cells target the same cell 
types, there is no evidence that they impede each other’s function. 
The induction of regulatory T cells by MSC may be crucial for the 
long-term effects of MSC after infusion. Eggenhofer et al. (2012) 
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time point of rejection. Thus, MSC pre-sensitization in this model 
impaired the renal allograft outcome. In liver disease, it is thought 
that MSC act differently according to their pleiotropic spectrum 
of action, depending on the etiology, and pathophysiology of the 
specific liver disease. Thus, the anti-inflammatory, anti-apoptotic, 
and pro-proliferative features of MSC might be favorable in cases of 
chronic inflammatory liver diseases. Additionally, functional tissue 
replacement is warranted in cases of massive tissue loss in order to 
provide sufficient metabolic capacity, such as in acute liver failure 
and extended liver resections, as discussed by Christ and Stock 
(2012). Therefore, understanding the impact of MSC both on the 
molecular and cellular level and their interactions with the host 
liver tissue in a microenvironment created by the diseased liver, is 
important for the development of effective MSC therapy. Another 
interesting option is to administer MSC in combination with 
human hepatocytes; to support hepatocyte function, but moreo-
ver to minimize short-term rejection of the hepatocyte transplant. 
This would facilitate bridging the patient to liver transplantation, 
or help the patient through the critical phase of acute liver failure 
until the native liver recovers. This setting would enable allogeneic 
hepatocyte transplantation avoiding long-term immunosuppres-
sion and its adverse effects.
The translation of a cell-based therapy from bench to bedside 
is challenging under a regulatory framework involving multiple 
responsible authorities, EU members, and continents. Regulatory 
centralization has been introduced in the EU since 2009 but the 
remaining national procedures can be quite heterogeneous. As 
pointed out by Ancans, European Medical Agency (EMA), and 
National Competent Authorities (NCA) guidance documents, 
initiatives, and interaction platforms are available to make the 
regulatory framework more understandable and accessible for 
investigators both in the public and private sectors (Ancans, 2012). 
Good understanding of the regulatory framework is essential for 
product development; initial steps will determine the marketing 
authorization application stage. Therefore, early communications 
between researchers/clinicians and the NCAs and the EMA are 
advised. Resulting strategy improvements may facilitate MSC-
based medicine development and authorization in the European 
Union.
The tremendous therapeutic potential of MSC has once again 
been highlighted in this Research Topic. MSC can alleviate alloreac-
tivity, but also reduce inflammatory responses involved in ischemia/
reperfusion injury. We are encouraged by the results of the first 
clinical trials, however, as we have seen in this topic, there are still 
several questions to be resolved before MSC can be broadly applied 
in transplantation. The knowledge obtained from this Research 
Topic may aid to further development of MSC-based therapies in 
transplantation and tissue regeneration.
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